CTRI/2012/06/002721已完成3 期
Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study.
psherSmith Laboratories Inc0 个研究点目标入组 172 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Have completed the maintenance period of the P09-004 study.
- •2. Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
uncontrolled epilepsyEUCTR2009-017904-95-DEpsher-Smith Laboratories, Inc.275
进行中（未招募）
不适用
Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 StudyRefractory partial-onset seizures with or without secondary generalizationMedDRA version: 14.0Level: PTClassification code 10056209Term: Partial seizures with secondary generalisationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10040703Term: Simple partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034090Term: Partial seizures, complexSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10048674Term: Partial seizures with secondary generalizationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10010145Term: Complex partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034091Term: Partial seizures, simpleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017904-95-GRpsher-Smith Laboratories, Inc.172
进行中（未招募）
不适用
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset SeizuresRefractory partial-onset seizures with or without secondary generalizationMedDRA version: 14.0Level: PTClassification code 10056209Term: Partial seizures with secondary generalisationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10040703Term: Simple partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034090Term: Partial seizures, complexSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10048674Term: Partial seizures with secondary generalizationSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: PTClassification code 10010145Term: Complex partial seizuresSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10034091Term: Partial seizures, simpleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017904-95-HUpsher-Smith Laboratories, Inc.172
进行中（未招募）
1 期
Clinical Trial Extension Study with Avapritinib for Patients with Gastrointestinal Stromal Tumorsocally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)MedDRA version: 21.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005751-21-FRBlueprint Medicines5
进行中（未招募）
1 期
Follow on study for participants involved in the P09- 004 Study which examines if USL255 is safe in patients with refractory partial-onset seizuresEUCTR2009-017904-95-BEpsher-Smith Laboratories, Inc.275